Vanguard Asset Management
VIR icon

Vanguard Asset Management’s Vir Biotechnology VIR Stock Holding History

Vanguard Asset Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$784K Hold
76,928
– – ﹤0.01% 2003
2026
Q1 		$689K Buy
+76,928
New +$613K ﹤0.01% 1953

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Asset Management's VIR Position: Q2 2026 in Review

Vanguard Asset Management held its Vir Biotechnology (VIR) position steady in Q2 2026 at 76,928 shares worth $784K. The position accounts for ﹤0.01% of the portfolio, ranked #2003.

Vanguard Asset Management first reported a position in VIR in Q1 2026 and has held it in 2 quarters since. 222 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Vanguard Asset Management held 76,928 shares of Vir Biotechnology worth $784K as of Q2 2026.
  • Vanguard Asset Management left its Vir Biotechnology share count unchanged in Q2 2026.
  • Vir Biotechnology made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2003 holding.
  • Vanguard Asset Management first reported a position in Vir Biotechnology in Q1 2026 and has held it in 2 quarters since.
  • 222 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.